The effect of Apo CIII on cerebrovascular risk appeared stronger in subjects without signs of relevant atherosclerotic disease but with valvular heart disease (9), including patients with mechanical prosthetic heart valves and/or atrial fibrillation, i.e., well recognized conditions at risk of cardioembolic stroke. This evidence concerns the gene APOC3 and atrial fibrillation.